Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Inhibrx Biosciences, Inc.
| Metric | Inhibrx Biosciences, Inc. INBXHealthcare |
|---|---|
| Quality Score | 53 / 100 |
| Revenue (latest) | $1M |
| Net income (latest) | −$140M |
| Operating margin | −10386.5% |
| Net margin | −10773.5% |
| Return on equity | −1752.2% |
| Return on assets | −95.6% |
| Return on capital (ROCE) | −119.8% |
| Debt / equity | 17.33× |
| Revenue growth (YoY) | 550.0% |
| Altman Z″ (distress) | -7.18 |
| Accruals / assets | −7.0% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.